Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 8/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.43 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26479779 | 0.78 | HRH3 (0.52) | BRD4CREBBP | |
| SCHEMBL12095184 | 0.74 | CREBBP (0.39) | BRD4CREBBPCHKA | |
| SCHEMBL14802437 | 0.74 | GRM2 (0.46) | NSD2BRD4CREBBPGRM2 | |
| SCHEMBL29615362 | 0.72 | ALOX5AP (0.48) | NSD2CREBBPGRM2 | |
| SCHEMBL28956664 | 0.72 | ALOX5AP (0.48) | NSD2CREBBPGRM2 | |
| SCHEMBL3349243 | 0.72 | BRD4 (0.45) | BRD4CREBBPADORA2AADORA2BADORA1 | |
| Hydrochloric Acid SCHEMBL30171660 | 0.72 | CREBBP (0.38) | BRD4CREBBP | |
| SCHEMBL6523541 | 0.70 | BRD4 (0.43) | BRD4CREBBPADORA2AADORA2BADORA1 | |
| SCHEMBL26479121 | 0.70 | DYRK1A (0.46) | BRD4CREBBPADORA2AADORA2BADORA1 | |
| SCHEMBL24924342 | 0.69 | BRD4 (0.40) | BRD4CREBBPADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181235-B2 | Substituted pyridines for modulating the WNT signaling pathway | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| EP-2588453-B1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2015-04-01 | — | — | EP | disclosed |
| CN-102958917-B | Compositions and methods for modulating the wnt signaling pathway | IRM LLC (BM) | 2014-10-08 | — | — | CN | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | NOVARTIS AG (CH) | 2013-03-28 | — | — | US | disclosed |
| CN-102958917-A | Compositions and methods for modulating the wnt signaling pathway | IRM LLC | 2013-03-06 | — | — | CN | disclosed |
| WO-2012003189-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | IRM LLC (BM) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079328-A1 | COMPOSITIONS AND METHODS FOR MODULATING THE WNT SIGNALING PATHWAY | WNT3A, WNT1, WNT3 | NSD2 1471/4885BRD4 763/4885CREBBP 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.